Our Solution

Market Opportunity

A One Health Opportunity

Cancer is one of the leading causes of death in dogs, and owners increasingly seek the same standard of care they would expect for a family member. Yet treatment options remain limited: surgery, chemotherapy and radiation are costly, not widely available, and rarely control cancer once it has spread.

The same is true in people. Lung cancer is the leading cause of cancer death worldwide, and the lungs are a common site of metastasis. A therapy proven against lung metastases in dogs therefore addresses an unmet need in two species, through one programme.


Market demand is growing rapidly as Millennials and Gen Z, now major pet owners, drive pet humanization and demand for advanced care, with pet insurance seeing significant growth now covering cancer therapy. However, pet parents face very limited treatment options relying on toxic, outdated chemotherapies as veterinary oncology remains decades behind human medicine. This vast unmet need, combined with growing One Health investment, creates the right timing for introducing safer, more effective therapy solutions to life-threatening disease in companion animals.

  • Veterinary oncology is a ~$1.7B category growing toward ~$5B

  • One in four dogs develops cancer during their lifetime.

  • Insights from naturally occurring canine cancer can de-risk and accelerate human drug development

Our Solution

Nebumet: Inhaled Immunotherapy


Nebumet is an investigational, off-the-shelf inhaled immunotherapy for dogs with cancer that has spread, or is likely to spread, to the lungs. It delivers BCG, one of medicine's most established immune stimulants, directly to the airways as a fine mist, using a nebuliser. With multiple patent protections through 2045 and a clear regulatory pathway, Nebumet offers a compelling investment opportunity.


  • Novel delivery of established immunotherapy with >30 years of human safety data

  • Proof-of-concept study (NEBULA) in 30 dogs with advanced oral melanoma, alongside a GLP target-animal safety study

  • Planned route to veterinary market authorisation

Silhouette of a researcher examining a slide under a microscope with a blue background.

Science

The Scientific Foundation

Dogs develop cancer spontaneously, with intact immune systems, and their tumours share key features with human disease. That makes evidence from canine patients directly relevant to human medicine.

Nebumet works by triggering local immune activation in the lungs to combat cancer cells. Our technology is backed by safety and efficacy evidence across multiple species.

  • Local immune activation by BCG is well documented across species

  • Mechanism activates the body's immune system against cancer cells

  • Platform technology expandable to multiple cancer types and species

Today Dogs, Tomorrow Humans.

Through development of new treatment methods, research and data products will Immuvera Therapeutics create value for our shareholders.

Today Dogs, Tomorrow Humans.

Through development of new treatment methods, research and data products will Immuvera Therapeutics create value for our shareholders.

Today Dogs, Tomorrow Humans.

Through development of new treatment methods, research and data products will Immuvera Therapeutics create value for our shareholders.